33.35

5.28% -1.86

After Hours: 33.35

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Discussions Forecast

Kymera Therapeutics Inc stock is currently priced at $33.35, with a 24-hour trading volume of 779.82K. It has seen a -5.28% decreased in the last 24 hours and a -15.57% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $35.45 pivot point. If it approaches the $32.63 support level, significant changes may occur.

Previous Close:

$35.21

Open:

$34.28

24h Volume:

779.82K

Market Cap:

$2.04B

Revenue:

$78.59M

Net Income/Loss:

$-146.96M

P/E Ratio:

-12.08

EPS:

-2.76

Net Cash Flow:

$-137.31M

1W Performance:

-5.04%

1M Performance:

-15.57%

6M Performance:

+194.61%

1Y Performance:

+1.21%

1D Range:

$32.75

$34.29

52W Range:

$9.60

$45.31

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

857-285-5300

Address

200 Arsenal Yards Boulevard, Suite 230, Watertown

Employee

Twitter

Next Earnings Date

2024-05-02

Latest SEC Filings

KYMR's Discussions on Twitter

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks Investment Research

Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Benzinga

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

GlobeNewswire Inc.

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

GlobeNewswire Inc.

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire Inc.

Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know

Benzinga

Kymera Therapeutics Inc Stock (KYMR) Financials Data

Kymera Therapeutics Inc (KYMR) Revenue 2024

KYMR reported a revenue (TTM) of $78.59 million for the quarter ending December 31, 2023, a +67.84% rise year-over-year.

Kymera Therapeutics Inc (KYMR) Net Income 2024

KYMR net income (TTM) was -$146.96 million for the quarter ending December 31, 2023, a +5.07% increase year-over-year.

Kymera Therapeutics Inc (KYMR) Cash Flow 2024

KYMR recorded a free cash flow (TTM) of -$137.31 million for the quarter ending December 31, 2023, a +11.94% increase year-over-year.

Kymera Therapeutics Inc (KYMR) Earnings per Share 2024

KYMR earnings per share (TTM) was -$2.52 for the quarter ending December 31, 2023, a +12.50% growth year-over-year.

Kymera Therapeutics Inc Stock (KYMR) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Booth Bruce	Director	Mar 14 '24	Sale	39.98	55,779	2,229,927	819,151
Booth Bruce	Director	Mar 13 '24	Sale	42.23	139,255	5,880,415	828,830
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	115,090	4,859,993	4,676,075
Atlas Venture Fund X, L.P.	10% Owner	Mar 13 '24	Sale	42.23	24,165	1,020,422	828,830
Booth Bruce	Director	Mar 12 '24	Sale	41.98	162,918	6,838,813	852,995
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	134,647	5,652,072	4,791,165
Atlas Venture Fund X, L.P.	10% Owner	Mar 12 '24	Sale	41.98	28,271	1,186,741	852,995
Booth Bruce	Director	Mar 11 '24	Sale	42.85	51,184	2,193,148	881,266
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	42,302	1,812,586	4,925,812
Atlas Venture Fund X, L.P.	10% Owner	Mar 11 '24	Sale	42.85	8,882	380,562	881,266

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.